2022
Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms
Rindi G, Mete O, Uccella S, Basturk O, La Rosa S, Brosens L, Ezzat S, de Herder W, Klimstra D, Papotti M, Asa S. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Endocrine Pathology 2022, 33: 115-154. PMID: 35294740, DOI: 10.1007/s12022-022-09708-2.Peer-Reviewed Original ResearchConceptsNeuroendocrine tumorsNeuroendocrine neoplasmsSomatostatin receptorsWHO classificationNon-neuroendocrineDifferential diagnosisWHO Classification of EndocrineExpression of somatostatin receptorsWHO classification of neuroendocrine neoplasmsG3 neuroendocrine tumorsAssociated with germline mutationsPancreatic neuroendocrine tumorsClassification of neuroendocrine neoplasmsEctopic hormone productionLoss of RbLoss of ATRXSite of originComposite tumorMetastatic lesionsAberrant p53Amphicrine tumorsEpithelial neoplasmsPrecursor lesionsTheranostic biomarkersGermline mutations
1990
Aberrant hormone production from ovarian neoplasms: Strategies for diagnosis and therapy
Leach S, LaMorte A, True L, Flynn S, Schwartz P, Cahow C, Kinder B. Aberrant hormone production from ovarian neoplasms: Strategies for diagnosis and therapy. World Journal Of Surgery 1990, 14: 335-340. PMID: 2164282, DOI: 10.1007/bf01658520.Peer-Reviewed Original ResearchConceptsOvarian neoplasmsHormone secretionAblative proceduresACTH-producing pituitary adenomaBenign ovarian cystic teratomasHormone productionAberrant hormone secretionComplete preoperative evaluationOvarian cystic teratomaEctopic hormone productionOvarian strumal carcinoidSteroid hormone secretionMedian followOvarian resectionDistal pancreatectomyOvarian carcinoidSubtotal thyroidectomyTotal gastrectomyHormone excessPreoperative evaluationFemale patientsCystic teratomaEndocrine tumorsSelective vagotomyStrumal carcinoid
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply